Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

244.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Alnylam Pharmaceuticals's Earnings Outlook
Via Benzinga
(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
Via Benzinga
Analyst Expectations for Alnylam Pharmaceuticals's Future
Via Benzinga
Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?
Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues. 
Via Benzinga
Exposures Product Safety
Why Alnylam Pharmaceuticals Stock Is Sinking Today
Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss. 
Via The Motley Fool
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Expert Ratings for Alnylam Pharmaceuticals
Via Benzinga
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst. 
Via Investor's Business Daily
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... 
Via Benzinga
Topics ETFs
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am 
Via Benzinga
Exposures Product Safety
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why Newly Listed Korro Bio Shares Are Gaining Today
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases. 
Via Benzinga
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.